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licenses/by/4.0/).Abstract Background: Despite aggressive multimodal therapy, >50% of children with high-
risk neuroblastoma (HRNB) relapse. Survival after relapse is rare, and no consensus currently
exists on the most effective therapy.
Objective: To conduct a systematic review of the literature on effectiveness of re-induction
chemotherapy in children with relapsed HRNB.
Methods: Database searches were performed to identify studies looking at response to 1st line
chemotherapy for children >12 months at diagnosis with first relapse of HRNB. Studies not
reporting separate outcomes for HRNB patients or of refractory patients only were excluded.
Two independent reviewers extracted the data and assessed study quality using a modified
NewcastleeOttawa tool.
Results: Nine studies were identified fitting the inclusion criteria. All except one were single
arm cohorts, and two were retrospective database reviews from single centres. One was a mul-
ticentre randomised controlled trial. All used a version of the validated International Neuro-
blastoma Response Criteria with 8 recording best ever response and 1 at a specified time, and 5
had central review. The proportion of relapsed patients varied from 24 to 100% with 30e93%er and leukaemia group; COG, Children’s oncology group; CR, Complete remission; EFS, Event-free
a; INRC, International neuroblastoma response criteria; INRG, International neuroblastoma risk group;
ging system; MAT, Myeloablative therapy; MR, Mixed response; NANT, New approaches to neuro-
NR, Not reported; OS, Overall survival; PD, Progressive disease; PICO, Patients, intervention, comparison
T, Randomised controlled trial; SD, Stable disease.
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F. Herd et al. / European Journal of Cancer 111 (2019) 50e58 51receiving upfront myeloablative therapy. The response rate varied from 6 to 64%; however,
because of heterogeneity, studies were not directly comparable, and no single treatment
emerged as the most effective re-induction therapy.
Conclusions: To date, there is no clear superior re-induction therapy for 1st relapse of HRNB.
Randomised controlled trials with separate arms for relapsed versus refractory disease are
needed to determine optimal re-induction chemotherapy to act as a backbone for testing newer
targeted agents.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Background
Neuroblastoma (NB) is an embryonal tumour arising
from the sympathetic nervous system originating in the
adrenal gland or along the paravertebral sympathetic
chain. It is a heterogeneous tumour classified into three
risk groups (low, intermediate and high) depending on
age, extent of disease, histology and cytogenetic abnor-
malities. Around 50% are high-risk neuroblastoma
(HRNB) defined as unresectable or metastatic tumours
with amplification of the MYCN oncogene in any age
group or those over 18 months with metastatic disease
[1].
Despite aggressive multimodal therapy, overall sur-
vival (OS) for HRNB is <50% at 5 years with most
relapses (80%) occurring within 2 years of diagnosis [2].
Historically, survival after relapse was very rare. A re-
view of relapsed stage 4 patients in the International
Neuroblastoma Risk Group (INRG) database from
1990 to 2002 revealed 5-year OS of 8% and 4% for
MYCN amplified disease [3]. An Italian retrospective
review (1979e2004) found a 10-year OS for relapsed
stage 4 patients of 2% [4]. UK data from a pilot epide-
miological study found 3% OS at 10 years for relapsed
HRNB [2]. A recent Children’s oncology group meta-
analysis showed a 4-year progression free survival of
6% and OS of 15% for high-risk patients enrolled on
early phase trials for relapsed/refractory disease [5].
MYCN status, time to relapse and age have all been
shown to affect length of survival after relapse with
MYCN amplified disease progressing more rapidly, later
relapse having a longer survival, and older children
having a more chronic, smouldering disease [2e7].
There is no clear consensus on optimal therapy for
relapse and a lack of randomised clinical trials. A recent
review on relapse therapy for HRNB summarises the
rationale and data for various chemotherapeutic ap-
proaches and suggests future therapies [8] However, this
is an expert review, and there is no comment on study
quality or comparison of efficacy. Guidelines exist on
the Children’s Cancer and Leukaemia Group website,
[9] suggesting a number of different chemotherapeutic
regimes; they are not a systematic comparison nor do
they give a preference. To avoid unnecessary toxictreatment and to optimise cure, it is essential to identify
the most effective treatment in relapsed HRNB, which
will also provide a backbone for testing newer targeted
agents. The aim of this study was to undertake a sys-
tematic review of work, published or available in ab-
stract form, examining effectiveness of re-induction
chemotherapy in children with newly relapsed HRNB.
2. Methods
2.1. Literature search
The systematic review followed guidelines contained in
the NHS Centre for Reviews and Dissemination [10].
MEDLINE, EMBASE, Cochrane CENTRAL and
SCOPUS bibliographic databases from inception to
December 2017 were searched using NEUROBLAS-
TOMA and a combination of terms and their alterna-
tives: (i) RELAPS*, (ii) HIGH RISK/STAGE 4 and (iii)
TREATMENT/THERAPY/CHEMOTHERAPY/RE-
INDUCTION. The reference list of a previous review
paper was cross-checked [8]. Websites including
clinicaltrials.gov, American Society of Clinical
Oncology and Advances in Neuroblastoma Research
and Solving Kids’ Cancer were also reviewed for
details of any relevant studies.
2.2. Study selection
Randomised controlled trials (RCTs), single arm
observational studies and retrospective analyses where
the population studied was children with relapsed
HRNB (treated on a national high-risk protocol) were
included. Studies combining relapsed and refractory
patients were also included. The intervention assessed
was first-line chemotherapy for relapsed disease and
excluded patients with >2 lines of previous therapy. The
outcome measure was response rate defined by a vali-
dated tool such as the International Neuroblastoma
Response Criteria (INRC) [11,12]. An objective
response was defined as complete remission (CR) or
partial remission (PR). Studies were excluded if they
included patients at 2nd or subsequent relapse, studied
refractory disease only, were not published in English,
Fig. 1. Flow diagram of included studies.
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studies. Relapse was defined as recurrence or progres-
sion (any new lesion, soft tissue or bone) following an
initial response (including partial) to any NB therapy
[11].
Three authors of studies published in abstract format
were contacted via email and asked to provide full data.
All declined apart from one who had a follow-up paper
accepted for publication [13]. However, this article did
not meet the eligibility criteria because of inclusion of
heavily pre-treated patients with a median number of
prior relapses of two.
One reviewer (F.H.) assessed the papers for inclusion
using PICO criteria (patients, intervention, comparison
and outcome) from the record title and abstract. Full
papers were assessed in detail for eligibility, and any
controversies were reviewed by another independent
adviser (D.A.T.).
2.3. Data extraction
Study characteristics and results were extracted by two
independent reviewers (F.H. and N.O.B.) using a
specially designed proforma (Supplementary Table 1).
Trial methodology/quality was assessed subjectively and
using a modified version of the Newcastle Ottawa Tool
[14] for cohort studies after review of options [15]. A
third independent adviser (D.A.T.) reviewed anydiscrepancies between the two reviewers. A cut-off of
60% was chosen for the proportion of relapsed patients
and proportion of patients having initial high-dose
myeloablative therapy (MAT) and autologous stem cell
rescue for the study to be deemed a representative
sample, since this research was focussed on first relapse
of patients treated on a previous high-risk protocol.3. Results
Electronic searching yielded 766 records, and an addi-
tional five other records were identified making a total
of 771 records. Thirty-four full-text articles were
assessed for study eligibility, and nine studies met the
inclusion criteria. Most exclusions were because of all
stages of disease being included without subgroup
analysis or patients receiving more than two previous
lines of chemotherapy (Fig. 1).
The characteristics of the nine included studies
[16e24] are detailed in Table 1. The studies were un-
dertaken between 1999 and 2015 and published between
2003 and 2017. Six were single arm, prospective studies
with small cohorts of relapsed and refractory patients
(25e40 patients) [17e19,21e23]. One study had three
different treatment arms depending on whether the pa-
tient had a central line in situ, and then a dose escalation
was performed after the toxicity was deemed acceptable
Table 1
Summary of included studies and their characteristics.
Study Type Patient no. Aim/intervention % Relapsed % MAT
Ashraf 2013 [16] Retrospective database review in
single centre
27 Describe response, survival and
toxicity of cyclophosphamide and
topotecan in children with 1st
relapse of NB
96 93
Bagatell 2011 [17] Prospective single arm cohort in
COG centres
27a Determine response rate of
irinotecan and temozolomide in
relapsed/refractory NB
77 NR
Di Giannatale 2014 [18] Prospective single arm cohort in
Europe
38 Assess objective response rate of 2
cycles of topotecan &
temozolomide chemo
66 61
Garaventa 2003 [19] Prospective single arm cohort in
Italy
25 Evaluate anti-tumour activity and
tolerability of topotecan/
vincristine/doxorubicin) in children
with advanced NB
24 52
Kushner 2010 [20] Retrospective database review in
single centre
30a Assess likelihood of response to
high dose cyclophosphamide/
topotecan/vincristine
100 70
Rubie 2006 [21] Prospective single arm cohort in
Europe
25 Determine response rate of NB to
temozolomide
60 64
Simon 2007 [22] Prospective single arm cohort in
Germany
40 Trial of topotecan & etoposide in
the treatment of patients with
relapsed HRNB
100 30
Simon 2007 [23] Prospective single arm cohort in
Germany
33a Trial of topotecan/
cyclophosphamide/etoposide in the
treatment of patients with HRNB
100 52
Mody 2017 [24] Randomised Control Trial in COG
centres
35 Comparison of temozolomide &
irinotecan chemotherapy with
additional temsirolimus or
dinutuximab in 1st relapse of
HRNB
56 & 53 50 & 59
MAT, myeloablative therapy with autologous stem cell rescue; NR, not reported; NB, neuroblastoma; HRNB; high-risk neuroblastoma; COG,
Children’s oncology group.
a n Z number of participants from the entire cohort in eligible sub group(s).
F. Herd et al. / European Journal of Cancer 111 (2019) 50e58 53[22]. Two studies were single centre retrospective data-
base reviews [16,20]. Of the other studies, four were
single arm, prospective multicentre studies within one
country [17,19,22,23], and two were European multi-
centre studies [18,21]. Only one study [24] was a rand-
omised controlled study.
3.1. Evaluation of studies meeting inclusion criteria
All studies included patients with HRNB ranging from
three studies [20,22,23] comprising all relapsed patients
to just 24% in one study [19]. The percentage of patients
who had received MAT with stem cell rescue as prior
treatment varied from 30 to 93% but was not reported in
one study [17]. Only one study documented prior use of
immunotherapy [24]. In some studies, only certain sub-
groups of the total study cohort were suitable for in-
clusion: one study [17] split their cohort into two strata
with 28 patients in stratum 1 who had measurable dis-
ease, but only 50% of these were stage 4 at diagnosis and
others stage 1e3. Not all of these non-stage 4 patients
had MYCN amplification, and therefore not all were
defined as high-risk patients. Stratum 2 had 27 patients
with disease evaluable by bone marrow or meta-iodobenzyl guanidine (mIBG) only, and all were high-risk at
diagnosis so only this arm was included. Another [20]
reported a total of 126 patients split into
four groupsdnew recurrence, primary and secondary
refractory and progressive disease. Only the subgroup of
new recurrence (30 patients) was included. A further
study [23] included a total of 44 patients split into two
cohorts: 33 had new recurrences and were included, and
11 were newly diagnosed patients, so were excluded.
3.2. Response assessment
Table 2 provides a description of response assessments
performed in each study and outcome. All studies
described an objective response rate to treatment using
validated criteria, although for two, this was a second-
ary outcome [22,23]. All studies used the INRC [11],
although one study [16] defined it as the New Ap-
proaches to Neuroblastoma Therapy criteria, which is a
modified version of INRC. Most described best ever
response, but one used response at a pre-defined time
point [17]. Eight of the studies defined response as CR
and PR, but one study included mixed response (MR)
[16]. Response varied from 6 to 64% (Fig. 2).
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Fig. 2. Bar chart displaying the objective response rate (complete remission & partial remission) to different chemotherapeutic strategies
detailed in Table 1. C/T, Cyclophosphamide/Topotecan; T/I, Temozolomide/Irinotecan; T/T, Topotecan/Temozolomide; TVD, Top-
otecan/Vincristine/Doxorubicin; CTV, Cyclophosphamide/Topotecan/Vincristine; Temo, temozolomide TCE, Topotecan/Cyclophos-
phamide/Etoposide; T/E, Topotecan/Etoposide; T/I/T, temozolomide/Irinotecan/Temsirolimus; T/I/D, temozolomide/Irinotecan/
Dinutuximab. *Mixed response is included in response
Table 2
Summary of response assessment in each study.
Study Drug Timing of response assessment Response rate (%)
Ashraf 2013 [16] Topotecan/cyclophosphamide Best 63a
Bagatell 2011 [17] Temozolomide/irinotecan After 3 cycles 19
Di Giannatale 2014 [18] Temozolomide/topotecan Best 24
Garaventa 2003 [19] Topotecan/vincristine/doxorubicin Best 64
Kushner 2010 [20] Cyclophosphamide/topotecan/vincristine Best 52
Rubie 2006 [21] Temozolomide Best 20
Simon 2007 [22] Topotecan/etoposide Best 47
Simon 2007 [23] Topotecan/cyclophosphamide/etoposide Best 61
Mody 2017 [24] Temozolomide/irinotecan
þ temsirolimus
þ dinutuximab
Best 6
53
a Denotes that the response includes mixed response.
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Study quality is shown in Table 3. Two studies were not
as representative of the desired patient group because
of a low percentage of relapsed patients in the cohort
and the low number who had received previous high-
dose chemotherapy treatment, respectively [19,23]. All
studies described treatment exposure and adherence
adequately. All studies used a validated tool for
response assessment with five studies having central re-
view of response, but little information was provided
about blinding of reviewers [17e19,21,24]. Since the
primary outcome was response, there was no require-
ment for long follow-up, and all patients were available
for assessment. Two studies were retrospective single-
centre studies, so were not representative of a wide
cohort. Because only one study [24] was a randomised
controlled study, a formal tool for quality assessmentwas not used, but appropriate methods of random-
isation were used, and the two arms were relatively
similar for important prognostic characteristics
including MYCN status. The only difference was the
percentage with bone marrow disease, which was 33% in
the temsirolimus arm and 76% in the dinutuximab arm.
4. Discussion
Historically, trials undertaken in relapsed neuroblas-
toma describe a very heterogeneous patient group.
Often, relapses of all stages of disease are included as
well as inclusion of a combination of refractory and
relapsed patients. This review focussed on relapsed
HRNB. Relapsed patients respond differently compared
with refractory patients [19,20], with the latter less likely
to show an objective response to chemotherapy but with
a longer time to progression and better OS [25]. One
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However, the remaining studies comprised predomi-
nantly relapsed patients with three having an entirely
relapsed cohort. MYCN amplification is associated
with a poorer OS and a shorter survival time post
relapse [2,3,26,27]. Older patients without MYCN
amplification often have a more chronic, smouldering
disease with longer survival [6]. Therefore, age distri-
bution and presence of MYCN amplification is
important in interpretation of results. Seven studies
reported the proportion of patients with MYCN
amplification, and this ranged from 10 to 38%. The
percentage of stage 4 patients with MYCN amplifica-
tion is around 30% [28], and in high-risk disease, this is
slightly higher because of localised MYCN amplified
tumours being included. A pilot study of relapsed pa-
tients found the rate of MYCN amplification to be
42%, [2] so the proportions reported in these studies are
slightly lower than expected. Relapses occurring earlier
after diagnosis are associated with a shorter length of
survival [3,27], but the effect of other prognostic fac-
tors (age, MYCN amplification and time to relapse)
were not reported in studies included in this review.
Neuroblastoma staging is standardised worldwide
using the International neuroblastoma staging system
and INRG criteria [1,11]. However, the decision to
treat patients on national high-risk protocols varies,
e.g. in most of Europe, HRNB is defined as patients
over 12 months with metastatic disease, MYCN
amplified localised unresectable disease and infants
with MYCN amplified metastatic disease [1]. However,
German protocols include MYCN amplified resectable
tumours on their high-risk protocols [29,30] but
exclude metastatic disease without MYCN amplifica-
tion diagnosed between 12 and 18 months. Both
German and North American protocols include chil-
dren over 18 months with unresectable localised tu-
mours showing International Neuroblastoma
Pathology Classification unfavourable histology with
or without unfavourable genetics. Thus, patient groups
may be slightly different, potentially affecting outcome
and response.
Not all centres use MAT and stem cell rescue in
upfront treatment of HRNB. Refractory patients are
less likely to have had previous MAT or immuno-
therapy. Response to relapse therapymay be different in
those who have had priorMAT or immunotherapy. The
included studies varied with respect to the proportion
who had received prior MAT with four studies not
having the desired 60% of patients having this treatment
[19,22e24]. Studies also lacked description of on-going
therapy after the regimen reported in the papers. Some
studies continued until disease progression, and others
were for a prescribed number of cycles, with the aim of
obtaining a response and then continuing to consoli-
dation therapy (although this was not described). In
most therapeutic phase III trials, OS and event-free
F. Herd et al. / European Journal of Cancer 111 (2019) 50e5856survival (EFS) are the primary outcome measures and
with the aim of ultimately improving OS of relapsed
HRNB. However, because of the low survival and lack of
standardised therapy post re-induction therapy and that
many of the included trials did not report EFS or OS,
comparison was impossible. Time to progression could
not be used because of the varying treatment strategies
given after the investigative treatment; therefore,
response rate was the only suitable outcome measure but
may not equate to survival.
The widespread use of standard definitions of
response allows confidence that studies are comparing
similar outcomes although one study included MR [16].
In 2012, revisions were made to the INRC to use
Response Evaluation Criteria in Solid Tumours for
response assessment of primary and metastatic soft tis-
sues sites and to classify bone marrow involvement of
5% as minimal disease allowing these patients to be
eligible for a PR depending on other site responses.
Urinary catecholamine levels were removed from
response assessment [12]. These changes arose with the
advent of more modern imaging technology and a lack
of sensitivity and specificity from the older techniques.
Therefore, we recognise that even though validated
INRC was used throughout the included studies, they
have limitations and are not now the gold standard
reassessment tool. The use of central review in five of the
studies helped to reduce bias in response categorisation.
Whilst direct comparisons are limited, it was inter-
esting that one study [21] reported a response rate (RR)
of 20% to temozolomide alone, and two other studies
[17,18] assessing temozolomide with the addition of a
second agent such as irinotecan or topotecan were very
similar (19 & 24%), yet the RCT study [24] showed that
the temozolomide/irinotecan and temsirolimus arm had a
disappointing response rate of just 6%. It is not clear why
it was so much lower in this group. There were no major
differences in the patients included in these studies with a
mix of relapsed and refractory patients mostly with
metastatic disease. It may be worth noting that the three
regimes with a >60% response rate contained topotecan
[16,19,23]. In the United States, topotecan has been
moved into frontline treatment because of its efficacy at
relapse in the hope that it could reduce relapse rate [31].
A double-blind RCT is the gold standard method for
comparison of therapeutic efficacy. A large phase II
RCT, comparing cyclophosphamide and topotecan with
topotecan alone demonstrated a slight, but non-
significant improvement in response in the combina-
tion arm, which did not translate into improvement
in survival [26]. This study was excluded because
of inclusion of nonehigh-risk patients, without separate
high-risk analysis [30]. A pilot study of temozolamide,
irinotecan, rapamycin and dasatanib (RIST) in relapsed
and refractory neuroblastoma patients published in ab-
stract form showed an objective major response rate
(CR and PR) of 71%, and a larger trial is now underway[32]. The on-going European BEACON trial will pro-
vide additional information on potentially suitable
backbone chemotherapy [33]. A non-randomised cohort
study found no benefit of adding bevacizumab to
temozolomide and irinotecan in relapsed and refractory
patients, and it will be important to see if this is
confirmed by the BEACON study too [13]. This review
is limited by the strict inclusion criteria, which were
chosen at the outset in order not to replicate previous
work and with the aim to identify the best treatment for
patients at first relapse with the intention of cure rather
than palliation. However, the authors recognise that this
has led to exclusion of several other regimes [26,34,35].
The current review is subject to publication bias since
all included studies were published in peer-reviewed
journals despite searching for unpublished literature.
Study heterogeneity with regard to risk group and pre-
vious treatments made formal quality assessment/
scoring difficult and direct comparison of results and
meta-analysis impossible.
5. Conclusion
Children with relapsed high-risk neuroblastoma show
response to a variety of chemotherapy agents. However,
patient and prior treatment heterogeneity in published
studies precludes determination of the most effective re-
induction strategy for children with relapsed high-risk
neuroblastoma. International and perhaps worldwide
RCTs in patients having similar upfront treatments
powered to look at individual subgroups (relapsed
versus refractory, MYCN amplification status) are
required to determine the ideal backbone upon which to
test novel targeted agents to try and cure more children
with relapsed high-risk neuroblastoma.
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